Huma Therapeutics Limited Has Closed a Series D Financing of Over $80 Million

Huma Therapeutics Limited has completed a Series D funding round of over $80 million and is now ready to launch the Huma Cloud platform with GenAI integrations . But what does this global AI healthcare company do?

What does Huma Therapeutics Limited do?

Huma Therapeutics Limited’s mission is to accelerate the adoption of digital solutions in healthcare and research, particularly for large-scale remote patient monitoring (RPM), use of companion apps to support patients during treatment and drug therapies, digital clinical trials, including decentralized, to accelerate medical research.

Its modular platforms are used by over 3,000 hospitals and clinics, with over 35 million screened users and 4 million registered users, and have helped power over 800 healthcare studies. The company works in the US, UK, Germany, Greece and Saudi Arabia, and collaborates with most of the major pharmaceutical companies.

Huma Therapeutics Limited Round

The Series D funding round, combined with investments from leading industry partners since the Series C round, has created a total equity issuance by Huma of over $80 million. The Series D round saw participation from new and existing strategic and financial investors, including AstraZeneca, HAT SGR’s Hat Technology Fund 4, Hitachi Ventures’ HV Fund, Bayer’s Leaps, and others.

Huma is also launching its cloud platform, a technology ecosystem designed not only to support the company’s digital health initiatives, but also to enable others to launch and scale their projects efficiently, aiming to reduce the time it takes to develop and launch digital health projects at scale.

Huma’s Next Steps

Huma Therapeutics has partnered with Google and others to develop new AI models that could enable users of its cloud platform to care for many more patients through AI. With the “10x Nurse” feature, for example, it significantly reduces administrative tasks.

New possibilities in Huma’s future include efficiently managing chronic diseases with fewer staff, using real-time monitoring systems to ensure patients are on the right treatment pathways while keeping humans in the loop, and combining the Huma Cloud platform with next-generation AI models. Huma also wants to support small startups and companies in launching digital solutions.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in StartupItalia. A third-party contributor translated and adapted the article from tthe original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us